A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-21

Study Completion Date

2021-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate efficacy and safety of AUR101 (RORgamma inhibitor) in patients with moderate-to-severe psoriasis.

Approximately 90 patients with chronic moderate-to-severe plaque psoriasis will be randomized to the 2 dose groups of AUR101 and one group of Placebo. The patients will receive the treatment for 12 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)

NCT04855721

Plaque Psoriasis

COMPLETED PHASE2

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

NCT03835481

Psoriasis

TERMINATED PHASE2

Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

NCT04428411

Plaque Psoriasis

COMPLETED

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

NCT02425826

Parapsoriasis

COMPLETED PHASE4

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

NCT00941031

Chronic Plaque-type Psoriasis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate efficacy and safety of two doses of AUR101 in patients with moderate-to-severe psoriasis.

Approximately 90 patients with chronic moderate-to-severe plaque psoriasis (defined as Psoriasis Area and Severity Index (PASI) ≥12 and Body Surface Area (BSA) involved ≥10%) will be randomized to the 2 dose groups of AUR101 and placebo in the ratio of 1:1:1.

The patients in each arm will receive AUR101 of 400 mg twice daily or AUR101 600 mg twice daily or matching placebo twice daily for 12 weeks in a double blind, double dummy fashion.

Every patient will receive 12 weeks of treatment. All the patients will be followed up for 14 ± 2 days of their last dose for safety assessment.

A subset of approximately 25 patients, who consent, will be asked to come for plasma PK assessment in week 4 of dosing.

Efficacy evaluation will be done by PASI, DLQI and BSA assessment. Safety assessment will be done by AEs and regular lab assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Plaque-type Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm-1 400 mg BID

400 mg AUR101 twice daily

Group Type EXPERIMENTAL

AUR101

Intervention Type DRUG

Inhibitor of RORγ

Arm-2 600 mg BID

600 mg AUR101 twice daily

Group Type EXPERIMENTAL

AUR101

Intervention Type DRUG

Inhibitor of RORγ

Arm-3 - Matching Placebo BID

Matching Placebo twice daily

Group Type PLACEBO_COMPARATOR

Matching Placebo

Intervention Type DRUG

Drug-Placebo of AUR101 tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AUR101

Inhibitor of RORγ

Intervention Type DRUG

Matching Placebo

Drug-Placebo of AUR101 tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

No other names No other names

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Confirmed diagnosis of chronic plaque-type psoriasis, diagnosed at least 6 months before screening

2\. Psoriasis of at least moderate severity, defined as PASI≥12 and involved BSA≥10 % at screening and Day 1

3\. Adult males or females,≥18 to ≤ 65 years of age.

4\. Ability to communicate well with the investigator and to comply with the requirements of the entire study

5\. Willingness to give written informed consent (prior to any study related procedures being performed) and ability to adhere to the study restrictions and assessments schedule.

Exclusion Criteria

* 1\. History of erythrodermic, guttate, or pustular psoriasis within last 12 months

2\. Efficacy failure on any biologic (e.g. interleukin (IL) -17 antibodies or anti-TNF agents) for the treatment of psoriasis.

3\. Static 5-point IGA mod 2011 scale of 0 to 2 at screening or Day 1.

4\. BMI ≥ 35 kg/m2

5\. Current treatment or history of treatment for psoriasis with IL-17 or IL-12/23 antagonist biological agents within 6 months prior to study day 1

6\. Current treatment or history of treatment for psoriasis with other biological agents within 3 months prior to study day 1.

7\. Current treatment or history of treatment for psoriasis with non-biological systemic medications or phototherapy within 4 weeks prior to study day 1.

8\. Treatment with medicated topical agents within 2 weeks prior to study day 1.

9\. History or presence of any medical or psychiatric disease, or clinically significant laboratory at screening,

10\. Evidence of organ dysfunction

11\. Any major recent surgery history within 3 months prior to screening

12\. Alcohol abuse or drug abuse

13\. History of malignancy

14\. Positive for HIV, Hepatitis B or Hepatitis C at screening.

15\. Patient with known past history of systemic tuberculosis or currently suspected or known to have tuberculosis

16\. Patient expected to be started on anti-tubercular therapy either for treatment or prophylaxis of tuberculosis.

17\. Suspected tuberculosis infection as evident from a positive QuantiFERON TBGold test (QFT) at screening. Patients with a positive QFT test may participate in the study if further work up as per the opinion of the investigator .

18\. History of hypersensitivity or idiosyncratic reaction to any investigational RORgamma inhibitors or any of the excipients of study drug

19\. Past gastrointestinal surgery or recent (within 3 months) / current history of gastrointestinal disease.

20\. Positive pregnancy test for women of child bearing potential (WOCBP) at the screening or randomization visit

21\. Male patients with partners of childbearing potential not willing to use reliable contraception methods.

22\. Pregnant or lactating women or WOCBP who are neither surgically sterilized nor willing to use reliable contraceptive methods

23\. Has received another new chemical entity/investigational drug within 28 days or 5 half-lives of investigational drug prior to study day 1.

24\. Use of herbal remedies, mega dose vitamins and minerals during the 2 weeks prior to the first administration of investigational product.

25\. Patients who have received live or attenuated vaccine in the 4 weeks prior to study day 1.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No